Sa544 THE BURDEN OF WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN CROHN'S DISEASE, ULCERATIVE COLITIS, PSORIASIS AND PSORIATIC ARTHRITIS

2021 ◽  
Vol 160 (6) ◽  
pp. S-543
Author(s):  
David Hudesman ◽  
Philip Mease ◽  
Mark Lebwohl ◽  
Anita M. Loughlin ◽  
Page C. Moore ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Psoriatic Arthritis ◽  
Crohn's Disease ◽  
Work Productivity ◽  
Activity Impairment

Sa1827 PREGNANCY OUTCOMES IN WOMEN WITH PSORIASIS, PSORIATIC ARTHRITIS, CROHN'S DISEASE AND ULCERATIVE COLITIS TREATED WITH USTEKINUMAB

2020 ◽  
Vol 158 (6) ◽  
pp. S-442
Author(s):  
Sheri Volger ◽  
Ilia Tikhonov ◽  
Connie Lin ◽  
Christopher D. O'Brien ◽  
Colleen W. Marano ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Psoriatic Arthritis ◽  
Crohn's Disease ◽  
Pregnancy Outcomes

scholarly journals A New Validation of the Spanish Work Productivity and Activity Impairment Questionnaire—Crohn's Disease Version

2011 ◽  
Vol 14 (6) ◽  
pp. 859-861 ◽  
Author(s):  
Mercedes Vergara ◽  
Antònia Montserrat ◽  
Francesc Casellas ◽  
Albert Villoria ◽  
David Suarez ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Work Productivity ◽  
Activity Impairment

scholarly journals Psoriasis and inflammatory bowel diseases: pathogenetic pathways and the choice of biologic therapy (a literature review)

2019 ◽  
Vol 47 (6) ◽  
pp. 568-578 ◽  
Author(s):  
L. S. Kruglova ◽  
A. N. Lvov ◽  
A. V. Kagramanova ◽  
O. V. Knyazev
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Psoriatic Arthritis ◽  
Crohn's Disease ◽  
Genetically Engineered ◽  
Evidence Level ◽  
Frequent Administration ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Effector Cytokines

Psoriasis and inflammatory bowel disease (IBD) are multifactorial chronic immuno-inflammatory potentially disabling disorders with similar genetic factors and immunological pathways, in particular, genetic polymorphisms of IL-23R, which determines the signal IL-12/23-mediated pathway of immunopathogenesis. The emergence of genetically engineered biological agents has changed the prognosis for both psoriasis and IBD. The intersection of the therapeutic spectrum in psoriasis and IBD is a very important point when choosing the management strategy for these patients. Infliximab and adalimumab are effective in the treatment of psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis (evidence level 1A). Ustekinumab demonstrates effectiveness in the treatment of psoriasis, psoriatic arthritis (evidence level 1A) and Crohn's disease (evidence level 1B). Etanercept and secukinumab have been shown to be effective against psoriasis, psoriatic arthritis (evidence level 1A) and ineffective and even associated with exacerbation risk in Crohn's disease and ulcerative colitis. Inhibition of regulatory cytokines IL-12/23 also has a number of advantages compared to the blockade of effector cytokines (TNF-α, IL-17) due to potentially long-term and stable treatment results and less frequent administration.

scholarly journals P265 Work productivity and activity impairment in Spanish Crohn's disease patients

2012 ◽  
Vol 6 ◽  
pp. S115 ◽  
Author(s):  
F. Gomollón Garcia ◽  
Y. Gonzalez Lama ◽  
J. Hinojosa ◽  
M. Iglesias ◽  
M. Maroto ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Work Productivity ◽  
Activity Impairment

scholarly journals Effect of Adalimumab on Work Productivity and Indirect Costs in Moderate to Severe Crohn’s Disease: A Meta-Analysis

2011 ◽  
Vol 25 (9) ◽  
pp. 492-496 ◽  
Author(s):  
David G Binion ◽  
Edouard Louis ◽  
Bas Oldenburg ◽  
Parvez Mulani ◽  
Arielle G Bensimon ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Indirect Cost ◽  
Meta Analysis ◽  
Work Productivity ◽  
Cost Savings ◽  
Indirect Costs ◽  
Activity Impairment ◽  
One Year

OBJECTIVE: To assess the effect of adalimumab on work productivity and indirect costs in patients with Crohn’s disease (CD) using a meta-analysis of clinical trials.METHODS: Study-level results were pooled from all clinical trials of adalimumab for moderate to severe CD in which work productivity outcomes were evaluated. Work Productivity and Activity Impairment Questionnaire outcomes (absenteeism, presenteeism and total work productivity impairment [TWPI]) were extracted from adalimumab trials. Meta-analyses were used to estimate pooled averages and 95% CIs of one-year accumulated reductions in work productivity impairment with adalimumab. Pooled averages were multiplied by the 2008 United States national average annual salary ($44,101) to estimate per-patient indirect cost savings during the year following adalimumab initiation.RESULTS: The four included trials (ACCESS, CARE, CHOICE and EXTEND) represented a total of 1202 employed adalimumab-treated patients at baseline. Each study followed patients for a minimum of 20 weeks. Pooled estimates (95% CIs) of one-year accumulated work productivity improvements were as follows: −9% (−10% to −7%) for absenteeism; −22% (−26% to −18%) for presenteeism; and −25% (−30% to −20%) for TWPI. Reductions in absenteeism and TWPI translated into per-patient indirect cost savings (95% CI) of $3,856 ($3,183 to $4,529) and $10,964 ($8,833 to $13,096), respectively.CONCLUSION: Adalimumab provided clinically meaningful improvements in work productivity among patients with moderate to severe CD, which may translate into substantial indirect cost savings from an employer’s perspective.

scholarly journals P538 Pregnancy outcomes in women with psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis treated with ustekinumab

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S460-S460 ◽  
Author(s):  
A Geldhof ◽  
S Volger ◽  
C B Lin ◽  
C O’Brien ◽  
I Tikhonov
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Psoriatic Arthritis ◽  
Crohn's Disease ◽  
Pregnancy Outcomes ◽  
Congenital Anomalies ◽  
Outcome Data ◽  
Maternal Exposure ◽  
Live Births ◽  
Adverse Pregnancy

Abstract Background Ustekinumab (UST) is indicated for psoriasis (PSO), psoriatic arthritis (PsA), Crohn’s disease (CD), and ulcerative colitis (UC). The recommended dose in CD/UC is generally higher than in PSO/PsA. No adverse pregnancy outcomes were observed in preclinical studies.1 Here we present pregnancy outcomes from spontaneous reporting, clinical studies and registries. Methods This dataset includes pregnancies with maternal exposure to UST during pregnancy or within 3 months prior to conception reported to the manufacturer through April 2019. Results Overall, 478 maternal pregnancies (334 PSO, 124 CD, 11 UC, 9 PsA) were identified. Mean maternal age was 30.5 years. Most pregnancies (71.3%) resulted in live births (LB, [including 20 preterm births; PTB]). Spontaneous abortion (SA) was reported in 18.4% of cases. Congenital anomalies (CA) were reported in 3.8% (3.3% major CA [MCA]). Pregnancies with UST exposure throughout gestation (12.1%) resulted in 55 (94.8%) LB including 4 (7.3%) PTB, and 5 (8.6%) MCA. Among pregnancies with exposure in Trimester 1 (66.5%), 207 (65.1%) LB including 11 (5.3%) PTB, and 2 (0.6%) MCA were reported. Among PSO/PsA maternal pregnancies, rates were 72.3% LB, 2.0% CA (1.4% MCA), and 16.9% SA; among CD/UC maternal pregnancies, rates were 68.9% LB, 4.4% MCA and 22.2% SA. Conclusion Pregnancy outcome data following maternal exposure to UST showed that the prevalence of live births, spontaneous abortions and congenital anomalies were consistent with the general population and TNFi therapies. Pregnancy outcomes in women with CD/UC and PSO/PsA were generally comparable. No apparent safety signals were noted with exposure throughout pregnancy. Reference

Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease

2008 ◽  
Vol 30 (2) ◽  
pp. 393-404 ◽  
Author(s):  
Margaret C. Reilly ◽  
Laetitia Gerlier ◽  
Yves Brabant ◽  
Martin Brown
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Work Productivity ◽  
Activity Impairment
Sign in / Sign up

Export Citation Format

Share Document